VXRT 241018 1.50P (VXRT241018P1500) Stock Options, News & Quotes

0.71
+0.01+1.43%

15min DelayClose Oct 18 16:00 ET

0.81High0.71Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

wwwarrior

Oct 9 10:31

$Vaxart (VXRT.US)$ Up she goes.

wwwarrior

Oct 9 09:33

$Vaxart (VXRT.US)$ Let's go

Jaguar8

Sep 30 15:13

NEWS

$Vaxart (VXRT.US)$
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator —
— The sentinel cohort is being funded as part of the Phase 2b NextGen COVID-19 clinical trial, valued at up to $456 million through the Rapid Response ...

Trytosaveabit

Aug 28 07:17

Hmm. Update

$Vaxart (VXRT.US)$ Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Rafey Jan

Aug 26 14:46

$Vaxart (VXRT.US)$
Analyst writes that Vaxart's oral tablet could offer better immunity than traditional intramuscular vaccines, which have faced challenges.
Oppenheimer initiated with an Outperform rating and a price target of $4, representing significant potential upside.
“VXRT is uniquely positioned as a leading company developing oral vaccines against COVID-19, supported by one of the largest BARDA-funded Project NextGen Awards,” the analyst writes.
“We think oral vaccines hold unique proper...